Showing 760 news articles about Hepatitis C treatment

Filters Content type: Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Access to healthcare

Spaniards rally over hepatitis C drugs

Editor's pick
Press TV
12 January 2015
Hepatitis C treatment

Interferon-free combination therapy prevents recurrence of HCV after liver transplantation

Editor's pick
Eurekalert Inf Dis
9 January 2015
Hepatitis C treatment

VA, DoD spend more than $450M on costly hepatitis drug

Editor's pick
USA Today
9 January 2015
Hepatitis C treatment

Anthem selects Gilead as primary supplier of hepatitis C drugs

Editor's pick
Reuters
9 January 2015
Hepatitis C treatment

Gilead Strikes Hepatitis Drug Deal With CVS Health

Editor's pick
New York Times
7 January 2015
Hepatitis C treatment

Express Scripts explains exclusive AbbVie hepatitis C prescribing deal

Editor's pick
Wall Street Journal
7 January 2015
Hepatitis C treatment

Third of 2015 health basket expansion in Israel goes to hepatitis C

Editor's pick
Jerusalem Post
4 January 2015
Hepatitis C treatment

Even with New AbbVie Drug, Many Hepatitis C Patients Are Being Turned Away from Treatment

Editor's pick
Hepatitis C News
23 December 2014
Hepatitis C treatment

Gilead slides after hepatitis drug setback

Editor's pick
Financial Times (free registration required)
23 December 2014
Hepatitis C treatment

Hepatitis C patients stage sit-in to demand access to new treatment

Editor's pick
El Pais
20 December 2014
New & experimental hepatitis C treatment

US FDA approves AbbVie hepatitis C drug, costs $83319 for 12 weeks

Editor's pick
Reuters
20 December 2014
Hepatitis C treatment

Cigna's Demonstration of “Real World” Effectiveness for Hepatitis C New Drug

Editor's pick
Insurance News Net
17 December 2014
Pharmaceutical industry

Class Action Lawsuit Challenges Exorbitant Pricing of Gilead’s Hepatitis-C Drug Sovaldi

Editor's pick
Chimicles & Tikellis press release
12 December 2014
Hepatitis C treatment

Philadelphia Agency Sues Gilead Over Price Of Hepatitis Drug

Editor's pick
Nasdaq
11 December 2014
Hepatitis C treatment

Will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?

Editor's pick
Hepatitis C New Drugs
10 December 2014
New & experimental hepatitis C treatment

FDA declines to approve Bristol-Myers hepatitis drug

Editor's pick
Reuters
27 November 2014
Hepatitis C treatment

Deaths of Japanese patients prompt label change for simeprevir

Editor's pick
HCP Live
24 November 2014
Hepatitis C treatment

Ooh La La: France Negotiates a Steep Discount for Sovaldi From Gilead

Editor's pick
Wall Street Journal
21 November 2014
Hepatitis C treatment

NHS asks Nice to delay ground-breaking hepatitis C drug

Editor's pick
Channel 4 News (blog)
19 November 2014
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir)

Editor's pick
Gilead press release
19 November 2014
Hepatitis C treatment

Practical steps to eliminating hepatitis C: a consensus for London

Editor's pick
London Joint Working Group on Substance Use and Hepatitis C
17 November 2014
Hepatitis C treatment

Interim Revision of Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Editor's pick
AidsInfo
17 November 2014
Hepatitis C treatment

New HCV drugs pass muster in real world

Editor's pick
MedPage Today
11 November 2014
Hepatitis C treatment

Olysio (simeprevir) approved for use in combination with sofosbuvir

Editor's pick
Johnson & Johnson press release
7 November 2014